Melanoma Meltdowns, Biosimilar Betrayals, and the Eczema Enigma Exposed!
Description
Buckle-up Kids. Our Derms on Drugs are answering some of the hottest questions in dermatology again this week:
- Melanoma's Mental Massacre: Discover which patients are most likely to spiral into anxiety and depression after diagnosis and how we can help save their sanity!
- Biosimilar Backstabbing: Why do patients switched to biosimilars fare worse than newbies to psoriasis? We'll peel back the layers of this pharmaceutical puzzle.
- Eczema Epidemic Exposed: Hold onto your moisturizers, folks! We've cracked the code on why everyone and their itchy grandmother has atopic dermatitis. Spoiler alert: It's not just your genes being jerks!
- Air Pollution: The Silent Skin Assassin: Dr. Ian Myles spills the tea on how he caught air pollution red-handed in the great eczema explosion of the '70s. Urban dwellers, your skin's arch-nemesis has been unmasked!
But wait, there's more! We'll also dive into:
- The return of the zit: Predicting acne's revenge after isotretinoin
- Dupilumab: The accidental cancer crusader?
- Tralokinumab: Savior for dupilumab dropouts or just another letdown?
- Ferulic acid vs. Rosacea: The face-off you never knew you needed
- Cysteamine and hydroquinone duke it out in the melasma arena
- Digital mucous cysts: Because even your fingers deserve some drama
You’ll laugh, you’ll cry, you might even learn something new… Join Drs. Ferris, Zirwas and Patton for a new episode every Friday
Derms on Drugs is produced by Scholars in Medicine.
Guest: Ian A. Myles, MD, Mph
Guest Bio: Dr. Myles, Principal Investigator, Epithelial Therapeutics Unit, graduated with a B.S. in biology from Colorado State University in 2001 and then obtained an M.D. from the University of Colorado in 2005. He completed an internal medicine residency at The Ohio State University prior to beginning fellowship training in allergy and clinical immunology at NIH. He worked under the mentorship of Dr. Sandip Datta investigating the mechanistic details of susceptibility to S. aureus skin infections. In 2011, Dr. Myles became a commissioned officer in the United States Public Health Service Commissioned Corps. LCDR Myles has supported several USPHS missions, from the Ebola virus vaccine trial in West Africa to congressional Gold Medal Ceremonies at the U.S. Capitol. In 2013, he was awarded a position as an assistant clinical investigator in the NIAID Transition Program in Clinical Research. Dr. Myles received his M.P.H. from George Washington University in 2016. In 2018, Dr. Myles became the head of the newly formed Epithelial Therapeutics Unit to evaluate the efficacy and safety of a topical, live bacterial treatment for atopic dermatitis (eczema). He is currently a participant in the Lasker Clinical Research Scholars and Distinguished Scholars programs.
Links to Articles and Websites
3. The clinical, mechanistic, and social impacts of air pollution on atopic dermatitis
5. Environmental and behavioral mitigation strategies for patients with atopic dermatitis
6. Acne Relapse and Isotretinoin Retrial in Patients With Acne
9. Ferulic Acid in the Treatment of Papulopustular Rosacea: A Randomized Controlled Study
11. Effectiveness of surgical versus non-surgical interventions in treatment of digital mucous cysts
Melanoma Prognosis Calculator
http://www.lifemath.net/cancer/melanoma/outcome/index.php
Skinesa Defensin+ Probiotic Spray
United States
